Gritstone Bio Shares Outstanding 2017-2024 | GRTSQ
Gritstone Bio shares outstanding from 2017 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Gritstone Bio Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
116 |
| 2022 |
91 |
| 2021 |
79 |
| 2020 |
38 |
| 2019 |
34 |
| 2018 |
9 |
| 2017 |
2 |
| 2016 |
2 |
Gritstone Bio Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-06-30 |
143 |
| 2024-03-31 |
118 |
| 2023-12-31 |
116 |
| 2023-09-30 |
115 |
| 2023-06-30 |
115 |
| 2023-03-31 |
114 |
| 2022-12-31 |
91 |
| 2022-09-30 |
87 |
| 2022-06-30 |
86 |
| 2022-03-31 |
86 |
| 2021-12-31 |
79 |
| 2021-09-30 |
78 |
| 2021-06-30 |
77 |
| 2021-03-31 |
77 |
| 2020-12-31 |
38 |
| 2020-09-30 |
38 |
| 2020-06-30 |
37 |
| 2020-03-31 |
37 |
| 2019-12-31 |
34 |
| 2019-09-30 |
36 |
| 2019-06-30 |
34 |
| 2019-03-31 |
29 |
| 2018-12-31 |
9 |
| 2018-09-30 |
2 |
| 2018-06-30 |
2 |
| 2018-03-31 |
2 |
| 2017-12-31 |
|
| 2017-09-30 |
2 |
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
